HIV-1-infected CD8+CD4+ T cells decay in vivo at a similar rate to infected CD4 T cells during HAART

AIDS

Volumn 22, Issue 1, 2008, Pages 57-65

  Hughes, Gareth J ^a   Cochrane, Alexandra ^a   Leen, Clifford ^b   Morris, Sheila ^b   Bell, Jeanne E ^a   Simmonds, Peter ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

AIDS; CD8; Decay; HAART; Lymphocyte; Replication

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DAMAGE; CELL SELECTION; CELL TYPE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA DAMAGE; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; LYMPHOCYTE COUNT; PLASMA; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 37349065509     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f151b9     Document Type: Article

References (41)

1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
3. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain high functional HIV-specific CD8+ T cells. Immunobiology 2006; 107:4781-4789.
4. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10:806-810.
5. Phillips RE, Rowland Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453-459.
6. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412:334-338.
7. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004; 10:275-281.
8. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:282-289.
9. Livingstone WJ, Moore M, Innes D, Bell JE, Simmonds P, and the Edinburgh Heterosexual Transmission Study Group. Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Lancet 1996; 348:649-654.
10. Semenzato G, Agostini C, Chieco-Bianchi L, De Rossi A. HIV load in highly purified CD8+ T cells retrieved from pulmonary and blood compartments. J Leukoc Biol 1998; 64:298-301.
11. Imlach S, McBreen S, Shirafuji T, Leen C, Bell JE, Simmonds P. Activated peripheral CD8 lymphocytes express CD4 in vivo and are targets for infection by human immunodeficiency virus type 1. J Virol 2001; 75:11555-11564.
12. McBreen S, Imlach S, Shirafuji T, Scott GR, Leen C, Bell JE, et al. Infection of the CD45RA+ (naive) subset of peripheral CD8+ lymphocytes by human immunodeficiency virus type 1 in vivo. J Virol 2001; 75:4091-4102.
13. Saha K, Zhang J, Gupta A, Dave R, Yimen M, Zerhouni B. Isolation of primary HIV-1 that target CD8+ T lymphocytes using CD8 as a receptor. Nat Med 2001; 7:65-72.
14. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, et al. T-cell subsets that harbor human immunodeficiency virus in vivo: implications for HIV pathogenesis. J Virol 2004; 78:1160-1168.
15. Cochrane A, Imlach S, Leen C, Scott G, Kennedy D, Simmonds P. High levels of human immunodeficiency virus infection of CD8 lymphocytes expressing CD4 in vivo. J Virol 2004; 78:9862-9871.
16. + lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol 1998; 72:9054-9060.
17. Flamand L, Crowley RW, Lusso P, Colombini-Hatch S, Margolis DM, Gallo RC. Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. Proc Natl Acad Sci USA 1998; 95:3111-3116.
18. Kitchen SG, Jones NR, LaForge S, Whitmire JK, Vu B-A, Galic Z, et al. CD4 on CD8+ T cells directly enhances effector function and is a target for HIV infection. Proc Natl Acad Sci USA 2004; 101:8727-8732.
19. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006; 12:289-295.
20. Poles MA, Boscardin JW, Elliot J, Taing P, Fuerst MMP, McGowan I, et al. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Imuune Defic Syndr 2006; 43:65-68.
21. Biancotto A, Grivel J-C, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, et al. Abnormal activation and cytokine spectra in lymph nodes of persons chronically infected with HIV-1. Blood 2007; 109:4272-4279.
22. Cochrane A, Hughes GJ, Seaton RA, Simmonds P. First evidence of HIV infection of CD8 lymphocytes expressing CD4 during primary HIV-1 infection. AIDS 2005; 19:1237-1239.
23. Hughes GJ, Willey S, Cochrane A, Leen C, Bell JE, Simmonds P. Virus immunocapture provides evidence for CD8 lymphocyte derived HIV-1 in vivo. AIDS 2007; 21:1507-1513.
24. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997; 387:188-191.
25. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219.
26. Wong JK, Günthard HF, Havlir DV, Zhang Z-Q, Haase AT, Ignacio CC, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Nat Acad Sci USA 1997; 94:12574-12579.
27. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 2000; 6:82-85.
28. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4R T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
29. Strain MC, Little SJ, Daar ES, Havlir DV, Günthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418.
30. Han Y, Wind-Rotolo M, Yang H-C, Siliciano JD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007; 5:95-106.
31. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Leigh Brown AJ. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 1990; 64:864-872.
32. Semenzato G, Agostini C, Ometto L, Zambello R, Trentin L, Chieco-Bianchi L, et al. CD8+ T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbour human immunodeficiency virus type 1. Blood 1995; 85:2308-2314.
33. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000; 14:2805-2812.
34. Mourand-Joubert L, Marcellin F, Launay O, Hugon-Guiramond S, Gérard L, Yeni P, et al. Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:268-276.
35. Teague KT, Munn L, Zygourakis K, McIntyre BW. Analysis of lymphocyte activation and proliferation by video microscopy and digital imaging. Cytometry 1993; 14:772-782.
36. Chun T-W, Carruth L, Finzi D, Shen X, DiGuiseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
37. Zhou Y, Zhang H, Siliciano JD, Siliciano RF. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4R T cells. J Virol 2005; 79:2199-2210.
38. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St. Clair M, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70-79.
39. Smith K, Aga E, Bosch RJ, Valdez H, Connick E, Landay A, et al. Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004; 18:1953-1956.
40. Doeuk DC, Pickler LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
41. Miller JD, Masopust D, Wherry EJ, Kaech S, Silvestri G, Ahmed R. Differentiation of CD8 T cells in response to acute and chronic viral infections: implications for HIV vaccine development. Curr Drug Targets Infect Disord 2005; 5:121-129.